Background: Urachal cancer is one of the rarest and aggressive malignant diseases of the bladder; its incidence was 0.2% of all bladder cancers in 2012. It occurs in advanced stages, among stage IV tumors 58% die at 22 months. It is originated from urachal, an embryological structure that is present in 32% of the adult population.
Objective: To present a case series of urachal cancer in a third level medical facility.
Method: Case series. Clinical data from patients with of urachal cancer during 2011 to 2019 were analyzed. The variables included were age, gender, smoking, clinical stage, treatment and evolution. Descriptive statistics, measures of central tendency and dispersion were used.
Results: There were seven patients; three men and four women; the mean age was 54.4 years. The most frequent histological type was mucinous adenocarcinoma. Partial cystectomy was performed with bilateral pelvic lymphadenectomy in three (42.8%) patients, radical cystectomy plus bilateral pelvic lymphadenectomy in the remaining four (57.2% patients).
Conclusions: Urachal cancer is rare, clinical manifestations occur late. Hematuria is the most frequent clinical sign. The medium term prognosis is bad.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.24875/CIRU.19001597 | DOI Listing |
NPJ Precis Oncol
January 2025
University of California, Irvine, Orange, CA, 92868, USA.
Urachal cancer, a rare malignancy, generally presents in the clinical setting with advanced stages of disease. Systemic treatment with chemotherapy is generally utilized in this setting. However, there remains a paucity of data on the effectiveness of immune checkpoint inhibitors or targeted therapies for urachal cancer.
View Article and Find Full Text PDFInt J Mol Sci
December 2024
Department of Urology, Semmelweis University, Üllői Street 78/b, H-1082 Budapest, Hungary.
Urachal cancer (UrC) is a rare disease which is mostly diagnosed late due to symptoms caused by its local invasion to the urinary bladder. Given the lack of clinical trials and guideline recommendations for systemic treatment, a molecularly informed precision oncology approach is a viable option for UrC already in the early lines of systemic treatment. While single case experiences may provide valuable reference for later decision-making, well-documented clinical experience with off-label targeted treatments is limited to a few patients.
View Article and Find Full Text PDFThorac Cancer
December 2024
Department of Thoracic Surgery, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Clin Genitourin Cancer
December 2024
Department of Urology, Rush University, Chicago, IL, USA. Electronic address:
Introduction: Urachal carcinoma (UrC) is a rare, nonurothelial malignancy, comprising less than 1% of all bladder cancers. It usually affects males in their fifth to sixth decade and is often diagnosed at an advanced stage with metastasis. This study examines UrC population characteristics and management.
View Article and Find Full Text PDFCureus
June 2024
Department of Plastic and Aesthetic Surgery, Kitasato University School of Medicine, Sagamihara, JPN.
A urachal remnant is a rare condition characterized by the persistence of the urachus beyond birth, often presenting with symptoms such as umbilical effusion, periomphalitis, and abdominal pain. Surgical resection is the cornerstone of treatment, but ensuring complete removal of urachal epithelium at the resection margin remains a challenge. This case report focuses on evaluating resection margins of urachal remnants and reports the case of a 25-year-old woman with complaints of umbilical effusion and a mass.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!